in the absence of a submission from the holder of the marketing authorisation
saxagliptin (Onglyza®) is not recommended for use within NHS Scotland.
Indication under review: monotherapy in adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice77KB (PDF)
Medicine details
- Medicine name:
- saxagliptin (Onglyza)
- SMC ID:
- 958/14
- Indication:
- Monotherapy in adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd / AstraZeneca
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 10 March 2014
The marketing authorisation for saxagliptin (Onglyza) was amended to cover use in combination with other diabetes medicines in June 2017. This minor licence change will not be assessed.